Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

BACKGROUND: In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Here, we present patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Knop, Stefan, Mateos, Maria-Victoria, Dimopoulos, Meletios A., Suzuki, Kenshi, Jakubowiak, Andrzej, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Usenko, Ganna, Pour, Ludek, Cook, Mark, Grosicki, Sebastian, Crepaldi, Andre, Liberati, Anna Marina, Campbell, Philip, Shelekhova, Tatiana, Yoon, Sung-Soo, Losava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Wang, Jianping, Wroblewski, Susan, Kudva, Anupa, Gries, Katharine S., Fastenau, John, San-Miguel, Jesus, Cavo, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170980/
https://www.ncbi.nlm.nih.gov/pubmed/34078314
http://dx.doi.org/10.1186/s12885-021-08325-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170980/
https://www.ncbi.nlm.nih.gov/pubmed/34078314
http://dx.doi.org/10.1186/s12885-021-08325-2

Ejemplares similares